Advancing Design Strategy of PROTACs for Cancer Therapy

The document reviews advancements in the design strategy of PROTACs (Proteolysis Targeting Chimeras) for cancer therapy, emphasizing their potential to degrade cancer-related proteins by leveraging the ubiquitin-proteasome system. Recent developments include AI-driven strategies for designing effective compounds, the use of nucleic acid and peptide-based PROTACs, and the exploration of novel modalities like nanomaterials and alternative degradation pathways. PROTACs have shown success in targeting proteins such as androgen receptor, estrogen receptor, and KRAS, with some progressing into clinical trials. Challenges like poor cell permeability and off-target effects are addressed through optimized design strategies. The document underscores the importance of refining PROTAC design to enhance efficacy and expand the range of targetable proteins, with AI playing a crucial role in accelerating development.